Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (HKG:2566)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
8.20
-0.04 (-0.49%)
At close: Mar 6, 2026
Market Cap1.98B +31.2%
Revenue (ttm)1.43B -1.6%
Net Income135.25M -4.1%
EPS0.60 -15.5%
Shares Out241.52M
PE Ratio13.76
Forward PEn/a
Dividend0.06 (0.74%)
Ex-Dividend Daten/a
Volume34,000
Average Volume178,390
Open8.24
Previous Close8.24
Day's Range8.20 - 8.40
52-Week Range5.36 - 16.29
Betan/a
RSI31.11
Earnings DateMar 26, 2026

About HKG:2566

Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of biopharmaceutical products and medical devices. The company offers Guyoudao, a recombinant human bone morphogenetic protein-2 bone repair product; Jilifen, a human granulocyte colony-stimulating factor injection for neutropenia; Jijufen, a human interleukin-11 injection for chemotherapy-induced thrombocytopenia; and Jiouting, a palonosetron hydrochloride injection for nausea and vomiting induced by rad... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 1,629
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2566
Full Company Profile

Financial Performance

In 2024, HKG:2566's revenue was 1.37 billion, an increase of 6.35% compared to the previous year's 1.29 billion. Earnings were 138.60 million, an increase of 15.72%.

Financial numbers in CNY Financial Statements